project.pptx
- 1. Product Vision/Value Proposition: Draft TPP 1 Minimum Profile Target Profile Optimistic Profile Indication Mounjaro® (mown-JAHR-OH) is an Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with injectable medicine for adults with type 2 diabetes used along with diet type 2 diabetes used along with diet and exercise to improve and exercise to improve blood sugar (glucose) blood sugar (glucose) Mechanism of Action It works to stimulate first- and It works to stimulate first- and second-phase insulin secretion, second-phase insulin secretion, and reduces glucagon levels, both and reduces glucagon levels, both in a glucose-dependent manner. in a glucose-dependent manner. Tirzepatide was also shown to delay Tirzepatide was also shown to delay gastric emptying, lower fasting and gastric emptying, lower fasting and postprandial glucose concentration, postprandial glucose concentration, decrease food intake, and reduce decrease food intake, and reduce. body weight in patients with type 2 diabetes body weight in patients with type 2 diabetes Study Design Control trial
- 2. Draft TPP (cont’d) 2 Minimum Profile Target Profile Optimistic Profile Dosing 2.5 mg once weekly for 4 weeks. Continue to 5 mg once weekly for at least 4 weeks. 2.5 mg SC qWeek x 4 weeks initially; THEN increase to 5 mg SC qWeek If additional glycemic control needed, increase by 2.5-mg increments after at least 4 weeks at current dose Maximum dose: 15 mg SC qWeek Route injection under the skin once weekly injection under the skin once weekly (sc) Frequency 2.5 mg injected subcutaneously once weekly 2.5 mg injected subcutaneously once weekly Presentation/Strengt h 2.5mg, 5mg, 7mg, 10mg, 12.5mg 2.5mg/0.5mL ,5mg/0.5mL , and 15mg as a once weekly 7.5mg/0.5mL, 12.5mg/0.5mL 15mg/0.5mL Administration once weekly, any time of day, with or without meals. once weekly, any time of day, with or without meals.